Objectives: Magnetic resonance lymphography (MRL) in small animals is a promising but challenging tool in preclinical lymphatic research. In this study, we compared the gadolinium (Gd)-based nanoparticle AGuIX with Gd-DOTA for interstitial MRL in healthy rats and in a chronic rat hindlimb lymphedema model. Materials and Methods: A comparative study with AGuIX and Gd-DOTA for interstitial MRL was performed in healthy Lewis rats (n = 6). For this purpose, 75 μL of 3 mM AGuIX (containing 30 mM Gd-DOTA side residues) and 75 μL 30 mM Gd-DOTA were injected simultaneously in the right and left hindlimbs. Repetitive high-resolution, 3-dimensional time-of-flight gradient recalled echo MRL sequences were acquired over a period of 90 minutes using a 9.4 T animal scanner. Gadofosveset-enhanced MR angiography and surgical dissection after methylene blue injection served as supportive imaging techniques. In a subsequent proof-of-principle study, AGuIX-based MRL was investigated in a hindlimb model of chronic lymphedema (n = 4). Lymphedema of the right hindlimbs was induced by means of popliteal and inguinal lymphadenectomy and irradiation with 20 Gy. The nonoperated left hindlimbs served as intraindividual controls. Six, 10, and 14 weeks after lymphadenectomy, MRL investigations were performed to objectify lymphatic reorganization. Finally, skin samples of the lymphedematous and the contralateral control hindlimbs were analyzed by means of histology and immunohistochemistry. Results: AGuIX-based MRL resulted in high-resolution anatomical depiction of the rodent hindlimb lymphatic system. Signal-to-noise ratio and contrastto-noise ratio of the popliteal lymph node were increased directly after injection and remained significantly elevated for up to 90 minutes after application. AGuIX provided significantly higher and prolonged signal intensity enhancement as compared with Gd-DOTA. Furthermore, AGuIX-based MRL demonstrated lymphatic regeneration in the histopathologically verified chronic lymphedema model. Collateral lymphatic vessels were detectable 6 weeks after lymphadenectomy.
L
ymphatic imaging is an emerging field in preclinical research. It has been overshadowed for long by angiogenesis research because high-resolution imaging techniques were not available for the lymphatic vasculature. 1 Direct lymphography in small animals is difficult, and intralymphatic cannulation is not suitable for repetitive in vivo analyses. 2 Hence, interstitial contrast deposition with transport through lymphatic capillaries represents the logical solution. Several techniques have been established for interstitial lymphography in small animals, such as fluorescence microlymphography, 3 magnetic resonance lymphography (MRL), 4, 5 and near-infrared fluorescence lymphography. 6, 7 In contrast to fluorescence-based lymphography, interstitial MRL is not limited by superficial penetration depth and yields information on tissue quality (ie, fibrosis, fatty deposits). Besides lymphatic vessel imaging, it allows additional lymph node characterization and staging. 8 Interstitial MRL in animals has been performed with different contrast agents. These include gadolinium (Gd)-labeled dendrimers, 9, 10 macrocyclic Gd-complexes, 4, [11] [12] [13] Gd-labeled dextran, 14 and hepatobiliary contrast agents. 15 However, the translation of these macromolecules into clinical application is restricted by delayed renal clearance and uptake into the reticulo-endothelial system. Furthermore, interstitial MRL with commercially available extracellular Gd-chelates is markedly limited by nonspecific distribution. 12 Hence, an ongoing need exists for contrast agents with better suitability for preclinical and clinical MRL.
The Gd-based nanoparticle AGuIX has been proposed for theranostic applications including different imaging modalities and anatomical localizations. 16 The concept of detection and radiotherapy of malignant brain and lung tumors has been investigated in laboratory animals. [17] [18] [19] Intravenously applied AGuIX is currently under clinical investigation serving as a radiosensitizer for the treatment of brain metastases. Based on previous studies on pharmacodynamic and pharmacokinetic properties, we hypothesized that AGuIX might be particularly suited for interstitial MRL. For verification, we herein performed a comparative study with Gd-DOTA in healthy rats. Gadofosveset-based MR angiography served as a control experiment to illustrate the vascular system. In a subsequent proof-of-principle study, MRL investigations with interstitial AGuIX application were performed in a chronic lymphedema model of the rat hindlimb.
MATERIALS AND METHODS

Contrast Agents
AGuIX has been described previously in detail. 16 In brief, it consists of 10 Gd-DOTA species binding to a polysiloxane core. Compared with other nanoparticles, it has a rather small molecular mass of 8.5 ± 1.0 kDa with a mean hydrodynamic diameter of 3.0 ± 1.0 nm. The molecule size and the rigid structure yield substantial MR contrast enhancement with higher r1 relaxivities than for free Gd-DOTA. 20 Solutions were prepared freshly for each animal from dry substance at a concentration of 3 mM AGuIX, 145 mM NaCl, 2 mM CaCl 2 ·6 H 2 0, 5 mM HEPES, pH 7.4 from a sterile filtrated stock solution and sterile pure water (Aqua ad iniectabilia; B. Braun Melsungen AG, Melsungen, Germany). At a concentration of 3 mM, the nanoparticle solution contained 30 mM Gd-DOTA side residues.
Gd-DOTA (Dotarem; Guerbet, Aulnay-sous-Bois, France) served as control contrast agent. Gd-DOTA is clinically approved by the Food and Drug Administration for intravenous use with MR imaging in the brain (intracranial), spine, and associated tissues in adult and pediatric patients. Imaging properties of this agent in MRL have previously been characterized in different animal studies. 21, 22 The Gd-DOTA stock solution supplied at 500 mM was diluted to a concentration of 30 mM with sterile pure water. Subsequently, equal doses of Gd were applied with the corresponding contrast agents for the MR experiment.
For MRL, the fourth phalanx of both hindlimbs was injected intradermally with 75 μL of the contrast medium preparations using a 31-gauge syringe (Hamilton Bonaduz AG, Bonaduz, Switzerland).
For contrast-enhanced MR angiography, gadofosveset (Vasovist; Bayer, Leverkusen, Germany) was applied as an intravenous bolus injection at a dose of 0.2 mL/kg, equaling 0.03 mmol/kg body weight, as described previously. 23 Gadofosveset binds reversibly to endogenous serum albumin, resulting in a longer vascular residence time and a higher r1 relaxivity with an increase in blood vessel signal intensity (SI).
Animals
All experiments were performed with 3-to 4-month-old male Lewis rats (Janvier Labs, Le Genest-Saint-Isle, France) exhibiting a mean body weight of 390 ± 40 g. The animals were housed one per cage under a 12-hour day/night cycle and were fed ad libitum with water and standard pellet food (Altromin, Lage, Germany). All experiments were conducted in accordance with the European legislation on the protection of animals (Directive 2010/63/EU) and the National Institutes of Health guidelines on the care and use of laboratory animals (National Institutes of Health publication #85-23 Rev. 1985) and were approved by the local governmental animal care committee (permission number: 67/2015).
Experimental Protocol
In 6 healthy animals, a comparative study with simultaneous intradermal injection of AGulX in the right and Gd-DOTA in the left hindlimb was conducted. After contrast application, 6 repetitive MRL scans were performed. After MRL completion, gadofosveset was applied via a tail vein catheter, and MR angiography studies were performed. Finally, methylene blue was injected intradermally, the animals were killed, and the lymphatic system of the hindlimb was dissected under a stereomicroscope for illustration purposes.
In 4 animals, we investigated AGulX for lymphatic imaging in a chronic lymphedema model. Lymphedema was induced by means of popliteal and inguinal lymphadenectomy with subsequent irradiation. Magnetic resonance lymphography investigations were performed 6, 10, and 14 weeks after lymphadenectomy. After the last scan, the animals were killed and tissue specimens were processed for histological and immunohistochemical analyses.
Magnetic Resonance Imaging
Animals were examined in a horizontal-bore 9.4 T animal scanner (BioSpec Avance III 94/20; Bruker Biospin GmbH, Ettlingen, Germany) with a BGA12S gradient system (maximum field strength, 675 mT·m
; linear inductive rise time, 130 microseconds; maximum slew rate, 4673 mT/m per second) run with ParaVision 6.0.1 (Bruker Biospin GmbH). All animals were placed in supine position and transferred to the magnet tail-first. Imaging was performed using a linearly polarized coil developed for imaging of the rat abdomen with an inner diameter of 72 mm (Bruker Biospin GmbH). Imaging was performed in coronal orientation with a 3-dimensional (3D) gradient recalled echo (GRE) time-of-flight (TOF) sequence adjusted to the blood flow velocity. Because of the low flow velocities experienced perpendicular to the z axis, this approach led to a reduction of the SI from blood vessels in the hindlimbs. Finally, MR angiography was performed using a 3D GRE sequence with field of view and matrix settings identical to MRL. Scan duration was 14 minutes and 36 seconds for MRL and 15 minutes and 52 seconds for angiography sequences. Details of the sequence parameters are given in Table 1 .
MRL Data Processing and Analysis
Acquired image data were transferred to an external workstation. Multiplanar reconstruction in coronal, axial, and sagittal orientation, 3D maximum intensity projection, and quantitative analyses of 2-dimensional coronal MR images were performed with the 32-bit OsiriX v.4.1.2 software (Pixmeo Sarl, Bernex, Switzerland). For the 6 animals of the comparative study, lymph node enhancement after AGuIX and Gd-DOTA injection was quantified. For determination of signal-to-noise ratio (SNR), the entire popliteal lymph nodes were segmented manually by regions of interest (ROI). The resulting SIs on unenhanced and contrast-enhanced images were recorded and averages per lymph node and time point were calculated thereof. In addition, SI of the muscle tissue adjacent to the lymph node was assessed on the basis of ROI measurements. Noise was measured as average standard deviation (SD) of the background signal collected from 2 identically sized ROIs placed independently in the air next to the animals. Signal-tonoise ratio for each time point investigated was determined as follows:
From the SI data recorded for the segmented lymph nodes and adjacent muscle, highest SI values were extracted (SI Lnmax ; SI musclemax ), and maximum SNR for the popliteal lymph nodes and adjacent muscle of each animal per time point were calculated as:
For determination of maximum contrast-to-noise ratio (CNR LNmax ), ROIs were placed in muscle tissue next to the lymph nodes investigated, and the highest SI within the ROIs were recorded. Corresponding CNR LNmax was calculated as follows:
Maximum lymph node-to-muscle ratio (LN/muscle ratio) was calculated as:
Lymphedema Animal Model
Chronic lymphedema was established by combined surgical and radiation ablation of the lymphatic system in right hindlimbs. 24 The nonoperated left hindlimbs served as intraindividual controls.
Surgery
Rats were anesthetized by intraperitoneal injection of ketamine (80 mg/kg body weight; Ursotamin; Serumwerk Bernburg AG, Bernburg, Germany) and xylazine (6 mg/kg body weight; Rompun; Bayer, Leverkusen, Germany). After depilation of the right hindlimb, the animals were placed on an operation stage, kept warm with an infrared lamp, and the right paw was injected intradermally with 0.1 mL methylene blue 10% (Carl Roth GmbH, Karlsruhe, Germany). The collecting lymphatic vessels of the hindlimb were ligated microsurgically before piercing the biceps femoris (Fig. 1A) , and popliteal ( Fig. 1B) as well as inguinal fat pads were resected. Incisions were closed with 5/0 monofilament (Prolene; Ethicon, Johnson & Johnson Medical GmbH, Norderstedt, Germany). Postoperative analgesia was provided with subcutaneous buprenorphine (0.05 mg/kg body weight; Buprenovet; Bayer Vital GmbH, Leverkusen, Germany) and tramadol hydrochloride for 3 days (40 mg per 100 mL drinking water; Tramal; Grünenthal GmbH, Aachen, Germany). Wound healing and animal behavior were checked regularly.
Irradiation
For planning, a representative rat was scanned with a computed tomography scanner (Brilliance CT Big Bore; Philips Healthcare, Eindhoven, the Netherlands). The scan parameters were defined as 120-kV voltage, 450 mA with pixel spacing of 0.10 mm, and slice thickness of 0.75 mm. This planning data set was used to define the planning target volume (PTV) in the right groin (Fig. 1C) , and the treatment plan was calculated using the Pinnacle v9.8 planning system (Philips Healthcare). The PTV was expanded 6 mm and planned with a single 6-MV photon multileaf collimator field from anterior direction (Fig. 1D) . The dose grid was 1 Â 1 Â 1 mm and the prescribed dose was 20 Gy in a depth of 25 mm (Fig. 1E) . The mean dose in the PTV was 19.1 ± 1.1 Gy. The animals were irradiated 2 weeks after surgery.
Paw Thickness Measurements
Caliper-measured paw thickness represents a valid surrogate parameter for rodent hindlimb volumes. 25 Repetitive measurements in isoflurane anesthesia were performed over a period of 14 weeks.
Histology and Immunohistochemistry
Skin samples were fixed in 4% formalin, embedded in paraffin, and cut into 3-µm thick sections. Individual sections were stained with hematoxylin and eosin according to standard procedures. Using a BX60 microscope (Olympus, Hamburg, Germany) and the imaging software cellSens Dimension 1.11 (Olympus), epidermal thickness was assessed. For blinding purposes, a grid was applied, individual values were evaluated in 4 randomized ROIs per section, and average epidermal thickness was calculated. To evaluate the collagen density, additional sections were stained with Sirius red. Under polarized light, mature collagen fibers (type I) appear reddish due to birefringence. 26 The collagen content was assessed in 6 randomized ROIs per section. Individual thresholding was used to calculate the Sirius red-positive tissue fraction.
To quantify immune cell infiltration, sections were stained with a polyclonal rabbit antibody against CD68 (1:50; ab125212, Abcam, Cambridge, United Kingdom) and a polyclonal rabbit antibody against CD3 (1:100; ab166609, Abcam) followed by a biotinylated goat antirabbit IgG antibody (ready-to-use; Abcam). The biotinylated antibody was detected by peroxidase-labeled streptavidin (1:50; Sigma-Aldrich, Taufkirchen, Germany). 3-Amino-9-ethylcarbazole (Abcam) was used as chromogen. Cell infiltration was quantified in 10 randomized ROIs per section using the software package ImageJ. 27 For immunohistochemical analyses of lymphatic vessels, additional sections were stained with a polyclonal rabbit antibody against lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1) (1:600; ab14917, Abcam). A goat anti-rabbit IgG Alexa555 antibody (1:200; Life Technologies, Eugene, OR) served as secondary antibody. Cell nuclei were stained with bisbenzimide (1:500; Hoechst 33342, SigmaAldrich) for exact image merging. Quantitative analyses of 6 randomized ROIs per section were performed with ImageJ and included the determination of lymphatic vessel density and lymphatic vessel area.
Statistics
Data were analyzed for normal distribution and equal variance. Two groups were compared using the paired t test (parametric data) or the Wilcoxon signed rank test (nonparametric data). To test for time effects within groups, analysis of variance for repeated measurements (parametric data) or the Friedman test (nonparametric data) were applied followed by the Dunnett post hoc test. Data are given as mean ± standard deviation unless otherwise indicated. Dot plots are shown with the median as single line and the interquartile range (IQR, 25% to 75% data range) as continuous line. For box plots, the box includes the IQR and the whiskers illustrate at most 1.5 times the IQR. The horizontal line represents the median and an open dot represents the mean. Statistical significance was accepted for P < 0.05.
Statistical analyses were performed with SigmaPlot (Systat Software Inc, San Jose, CA) and R (R Core Team, Vienna, Austria). 28 
RESULTS
MRL in Healthy Animals
Lymphangiography
With the selected MR imaging strategies, both lymphatic and blood vessels of the rat hindlimb could be clearly discriminated (Fig. 2) . Magnetic resonance lymphography performed directly after AGuIX application allowed high-resolution depiction of the lymphatic vessel anatomy in vivo correlating to ex vivo hindlimb dissection after methylene blue injection (Fig. 2, B, D, and E) . The collecting lymphatic vessels were characterized by a typical appearance with varying diameter and strong contrast enhancement, whereas veins appeared smoother and less pronounced (Fig. 2, B and C) . Efferent lymphatic vessels (Fig. 2, B , F, and G) exhibited a tortuous course toward the inguinal region. Signal intensity of lymphatic vessels decreased over time, but typical characteristics were preserved (Fig. 3) . Afferent and efferent lymphatic vessels remained delineable up to 60 minutes after AGuIX injection. In MRL scans performed 75 and 90 minutes after administration, residual traces of the contrast medium could be detected in the lymphatic vessels with a substantial amount of AGuIX retained in the popliteal lymph node as well as at the injection site (Fig. 3, E and F) . In contrast, Gd-DOTA injection resulted in contrasting of veins, afferent and efferent lymphatic vessels 15 minutes after contrast application (Fig. 3A) . Initial contrast enhancement was stronger for the short saphenous vein than for the afferent lymphatic vessels. Venous contrast enhancement was reduced 30 minutes after administration, and lymphatic vessel imaging was improved at this time point (Fig. 3B) . However, lymphatic vessel delineation was markedly enhanced in AGuIX-injected hindlimbs, whereas Gd-DOTA was completely cleared from the injection site after 90 minutes (Fig. 3F) .
Lymphadenography
AGuIX and Gd-DOTA injections resulted in an early peak enhancement of the popliteal lymph node 15 minutes after injection (Figs. 3, 4 ) with a continuous washout throughout the 90-minute observation period. AGuIX SNR LNseg was significantly higher compared with Gd-DOTA for all experimental time points (Fig. 4G) . AGuIX injection resulted in a 7.3-fold increase in mean SNR LNseg from 9.5 ± 1.9 to 68.7 ± 14.1. Ninety minutes after administration, mean SNR LNseg still remained 2.7 times higher than initially recorded. In contrast, Gd-DOTA injection was associated with a SNR LNseg increase by a factor of 3.7 from 10.2 ± 2.1 to 37.7 ± 7.4. Furthermore, mean SNR LNseg in the Gd-DOTA group dropped to baseline already 60 minutes after administration. SNR LNmax measurements revealed an 11.5-fold increase in the AGuIX group from 19.9 ± 4.0 to 229.0 ± 72.5 (Fig. 4H) . Ninety minutes after administration, SNR LNmax still remained significantly elevated when compared with preinjection values. For Gd-DOTA injected hindlimbs, SNR LNmax rose 7.0-fold from 20.3 ± 4.0 to 142.0 ± 48.2 and returned to baseline level as early as 45 minutes after application.
Accordingly, CNR LNmax in the AGuIX group exhibited a 28.5-fold increase from 7.6 ± 3.3 before application to 216 ± 68.6 15 minutes after injection (Fig. 4I) . However, 60 minutes after contrast application, no significant difference to baseline was detectable. Gd-DOTA injection led to a CNR LNmax increase by a factor of 17.2, from 6.5 ± 1.9 to 117.9 ± 49.9 with return to baseline level 45 minutes after application.
Furthermore, LN/muscle ratio after AGuIX injection showed a 9.7-fold increase from 1.5 ± 0.2 before application to 14.4 ± 4.0 15 minutes after application (Fig. 4J) . Injection of Gd-DOTA led to a 6.2-fold increase of LN/muscle ratio from 1.4 ± 0.2 to 8.9 ± 3.3 with reduction to baseline level 45 minutes after administration.
Characterization of Chronic Hindlimb Lymphedema in Rats
All incisions healed uneventfully. Combined surgical and radiation ablation of the lymphatic system resulted in increased hindlimb volumes as indicated by paw thickness measurements (Fig. 5A) . Accordingly, the epidermal layer of the groin skin was significantly thicker in the lymphedema group (Fig. 5, B-D) . Moreover, histological and immunohistochemical analyses revealed typical hallmarks of chronic lymphedema, such as tissue fibrosis (Fig. 5, E-G) , immune cell infiltration (Fig. 5, H-K) , and increased density and dilatation of lymphatic vessels (Fig. 5, L-O) .
MRL in Chronic Hindlimb Lymphedema
Six weeks after lymphedema induction, multiple collateral lymphatic vessels draining toward the inguinal ligament were detectable, as illustrated by AGuIX-based MRL (Fig. 6A) . These newly visualized lymphatic vessels exhibited a different morphology with a higher variation in diameter. Accordingly, lymphatic reorganization on the dorsum of the paws after 6 weeks was characterized by a dense reticular network from which the new collateral lymphatic vessels originated (Fig. 6D) . At this time, residual dermal backflow was present around the ligated lymphatic vessels (Fig. 6 , E and F) as compared with nonoperated control hindlimbs (Fig. 6, G-I) . However, subsequent MRL investigations 10 and 14 weeks after surgery showed a decrease of collateral lymphatic vessels (Fig. 6, B and C) .
DISCUSSION
Magnetic resonance imaging of the lymphatic system exhibits several advantages. It has higher temporal and spatial resolution than radionuclide labeling and is suited for detailed 3D investigation of lymphatic vessels with a diameter in the submillimeter range. In the clinical setting, MRL has already been applied for detection of metastases that have segregated to sentinel lymph nodes, 29, 30 or for diagnosing lymphatic vessel abnormalities. 31 However, many MRL methods have not been translated from preclinical or clinical research to standard procedures for patients and contrast agents applied for this purpose are not clinically approved 29, 30 or used off-label. 31 In this study, we evaluated the investigational nanoparticle AGuIX for MRL in rats. Besides relaxivity (r1 and r2), the size of the nanoparticles of the contrast agent and its weight and lipophilicity are the factors that crucially determine pharmacodynamic and pharmacokinetic properties in vivo. Accordingly, Kobayashi et al 9 demonstrated that transport with lymphatic vessels, lymph node enhancement, and elimination from the lymphatic system are correlated to the size of the contrast agent. Larger particles cause strong and long-lasting contrast enhancement in lymph nodes, whereas small molecules are eliminated quickly. The pharmacokinetic properties of AGuIX fit well within these results. At a molecular weight of 8.5 kDa, AGuIX exhibits slowed transit through the lymphatic system. In fact, mean SNR of the popliteal lymph node remained significantly increased up to 90 minutes after AGuIX injection. Based on its larger hydrodynamic diameter and higher mass as compared with Gd-DOTA, AGuIX showed a limited transit from the interstitium into venous vessels and was predominantly drained from the injection site via lymphatic vessels. This effect could be visualized up to 60 minutes after injection. In contrast to the MRL studies performed with AGuIX, Gd-DOTA application primarily resulted in simultaneous enhancement of the short saphenous vein and lymphatic vasculature. Afferent lymphatic vessels were detectable up to 30 minutes after injection with only minor contrast enhancement. Yet, the effect of early venous enhancement using contrast agents with extracellular distribution may significantly impair diagnostic quality of MRL. Our experience with Gd-DOTA-based MRL is in accordance with results of contrastenhanced MRL performed in the clinical setting. Notohamiprodjo et al 32 described concomitant enhancement of veins and lymphatic vessels directly after contrast application in patients with lymphedema.
One limitation of this study consists in the rather long acquisition time of the high-resolution MRL sequences. Hence, the dynamics of AGuIX transport through the lymphatic system could not be investigated in detail. However, in comparison with Gd-labeled dendrimers, a faster transport of AGuIX through lymphatic capillaries and a shorter half-life in the lymphatic vasculature can be assumed. Analyses in a comparable setting demonstrated that the uptake of a 4-nm-sized nanoparticle fabricated by incubation of gadofosveset and human serum albumin peaks immediately after injection with subsequent drop-off. 33 In the present study, AGuIX performed better than Gd-DOTA with respect to immediate and sustained uptake into the popliteal lymph node. As a difference to dendrimer-based nanoparticles, 9 AGuIX was eliminated faster from the lymphatic system. The LN/muscle ratio calculation demonstrated washout from lymph nodes 60 minutes after intradermal administration. Decrease in SNR LNseg , SNR LNmax , and CNR LNmax was observed 30 minutes after administration. When compared with gadofluorine-based MRL contrast agents, 12 testing of AGuIX indicated preferable pharmacokinetics with prolonged signal enhancement in the lymphatic vessels and lymph nodes.
It has to be emphasized that the herein presented MRL experiments were performed at a magnetic field strength of 9.4 T. High field strengths facilitate high spatial resolution and are particularly advantageous for small animal MRL. This is reflected by the high quality of lymphatic vessels depiction presented in this study. However, performing MRL at high field strengths is ambivalent. At lower field strengths between 1.5 T and 3 T, chemical shift-and susceptibility-related artifacts are less common than at the high field strengths utilized in most animal scanners. Furthermore, the physical properties of contrast media vary with the external magnetic field strength applied. For both contrast media employed in this experimental study, a negative correlation of r1 relaxivity with magnetic field strength has previously been reported. 20 Desirable gains in SNR due to the strong magnetic field employed may therefore be counteracted by impaired contrast media effectivity.
The induction of chronic hindlimb lymphedema in rodents is difficult and requires invasive lymphatic ablation. 34 In the present study, we combined radical popliteal and inguinal lymphadenectomy with subsequent irradiation. To mimic the lymphatic damage of clinical cancer treatment most precisely, we did not leave a skin gap, an otherwise popular experimental procedure in rodents for the prevention of spontaneous lymphatic reconnection. 35, 36 Histopathological analyses 14 weeks after surgery revealed typical characteristics of chronic lymphedema, such as tissue fibrosis, immune cell infiltration, and an increase in lymphatic vessel density and area. In addition, hindlimb volumes estimated by paw thickness measurements were elevated in the lymphedema group throughout the 14-week observation period. Moreover, AGuIX-based MRL 6, 10, and 14 weeks after lymphadenectomy revealed characteristic findings of lymphatic reorganization.
Comparable lymphatic reorganization after popliteal lymphadenectomy has been observed in mice using near-infrared fluorescence imaging. 37, 38 One week after surgery, rupture of collateral lymphatic vessels with dermal backflow was reported. After 4 weeks, collateral pathways toward the inguinal lymph node were established and lymphatic vessels showed signs of maturation. 37 In our more invasive rat model, MRL 6 weeks after surgery demonstrated similar collateral lymph flow. Moreover, we observed residual dermal backflow close to the ligated lymphatic vessels. The newly visualized lymphatic vessels exhibited a greater variation in diameter when compared with nonoperated hindlimbs. Importantly, MRL-based analysis of lymphatic vessel maturation remains limited to morphological characterization. In contrast, near-infrared fluorescence imaging allows dynamic analyses, such as the assessment of lymphatic vessel contractility. 39 Surprisingly, after 10 and 14 weeks, fewer collateral lymphatic vessels were detectable. This finding may indicate increased lymphangiogenesis-independent interstitial fluid drainage. 40 However, it remains unclear to what extent upstream interruption of the lymphatic pathway (ie, inguinal lymphadenectomy) or additional irradiation contributed to this phenomenon. Importantly, fibrosis has been shown to be a strong inhibitor of lymphatic regeneration. 41, 42 Hence, we speculate that irradiation-induced tissue fibrosis was the major counterpart of lymphatic reorganization in the advanced stage of the herein investigated rodent lymphedema model.
Taken together, this study demonstrates that AGuIX-based MRL may be ideally suited for preclinical lymphatic imaging in rodents at high field. It yields sufficiently high spatial and temporal resolution for anatomical imaging of lymphatic vessels with diameters around 200 μm. Thus, AGuIX-based MRL may be a suitable tool to assess lymphatic regeneration after reconstructive lymphedema surgery, such as vascularized lymph node transfer 43 or lymphaticovenular anastomosis. 44 With shorter scan duration, high-resolution MRL could even be suitable to analyze lymphatic vessel function or lymphatic drainage, as already reported by other groups. 45 Moreover, AGuIX has been investigated in mouse models of lung cancer 16 and melanoma. 46 In both tumor types, restraint of the contrast agent in induced lesions has been observed 24 hours after application. This may pave the way for metastasis tracking after intradermal injection. 
